Record £16.9m for Oxford spinout designing stem cell drugs to treat age-related disease

11 May 2016

_{Image courtesy of Shutterstock}

One of the most ambitious Oxford spinouts to date is on route to becoming a powerhouse in age-related regenerative medicine, developing drugs which can treat cancer, neurodegenerative diseases, heart failure, macular degeneration and other major age-related conditions.

OxStem has raised a record £16.9m, and established strategic partnerships with world class biotechnology companies and individual investors in this rapidly emerging scientific space.

Read more (ISIS Innovation website)

No limit to the benefits of exercise in reducing the risk of cardiovascular disease

14 January 2021

A new study led by the University of Oxford on over 90,000 participants shows that there is no upper threshold to the benefits of exercise in reducing the risk of cardiovascular disease – ‘every move counts towards better cardiovascular health.’

Accurate predictions of ovarian cancer outcome possible with new classification system

14 January 2021

The new, Oxford-developed method for subtyping ovarian cancer has been validated in a recent collaboration between the University of Oxford and Imperial College London. Dubbed the ‘Oxford Classic’, researchers have demonstrated that it enables the accurate prediction of patient disease outcome, as well as the development of new targeted cancer therapies.

Oxford scientists: how we developed our COVID-19 vaccine in record time

13 January 2021

Accidental awareness in obstetric surgery under general anaesthesia more frequent than expected

13 January 2021

The largest ever study of awareness during obstetric general anaesthesia shows around 1 in 250 women may be affected, and some may experience long-term psychological harm.

Are sleep trackers accurate? Here’s what researchers currently know

12 January 2021

Why we need to test COVID-19 tests